Your latest cannabis business info from Europe

Your latest cannabis business info from Europe

2024-01-04

EDQM releases cannabis flower and cannabidiol standards

EDQM: release of cannabis flower standards for system suitability and cannabidiol for cannabis CRS

The long-awaited monograph for Cannabis flower (3028) has been released by the European Pharmacopoeia (Ph. Eur.) Commission, marking a revolutionary step forward in the standardization of medicinal cannabis. Within the medicinal cannabis sector, the preview of this monograph in October 2023 generated a great deal of curiosity. Building on this enthusiasm, two crucial standards have recently been made available by the European Directorate for the Quality of Medicines & Healthcare (EDQM): cannabidiol for cannabis CRS and cannabis flower for system suitability HRS.

New cannabis requirements for EDQM

One important criteria for system suitability is included in the recently adopted monograph on cannabis flower (3028): Cannabis flower for system suitability HRS. The catalogue code for this standard is now Y0002440. It establishes the standard for cannabis flower’s quality and effectiveness across a range of analytical techniques. It offers labs a thorough manual to guarantee the accuracy and repeatability of analytical data pertaining to cannabis flower.

Cannabidiol for cannabis CRS is another crucial criterion that the EDQM has set, in addition to the Cannabis flower for system suitability HRS. The catalogue code Y0002422 dentifies it. This standard is especially concerned with cannabidiol. This standard’s inclusion underlines the necessity for standardized testing procedures and recognizes the growing significance of CBD in medical applications.

Advantages of adopting standards

The medicinal cannabis sector will profit greatly from the recently issued standards. These guidelines act as a pillar to guarantee testing consistency. It provides a standard foundation that ensures trustworthy and consistent outcomes in a range of lab settings.

They also make it possible for producers to put strict quality control procedures in place that guarantee the potency and purity of medicinal cannabis products. Under these circumstances, following the guidelines becomes crucial. It is assisting businesses in fulfilling legal obligations and boosting credibility and acceptability in the medical marijuana industry. Last but not least, the emphasis on standardization is crucial to Research Advancements since it offers a common language and technique that not only makes it easier for institutions and researchers to collaborate, but also stimulates more thorough and trustworthy research projects in the area.

Consequences for the medical cannabis sector

All things considered, the publication of these recommendations marks a significant turning point for the medicinal cannabis industry. This trend toward uniformity is anticipated to support patient safety, expedite research, and increase the legitimacy of medical cannabis products.

As more companies and labs follow these standards, the industry may anticipate good movement towards increased quality, consistency, and reliability in medicinal cannabis products. This development helps individuals who grow and test medicinal marijuana as well as those who want to do further study and protect the health of patients who use these products for therapeutic purposes.

Related

Medical cannabis industry: Swisscann and GMP certification

Cannabis tampon startup 

POPULAR

Aldi Süd sells hemp amid Germany’s looming cannabis legalization

Prescriptions for medical cannabis in Poland: 100 times more!